Dr. Yining Zhao is the Chief Executive Officer and Co-Founder at Hangzhou Just Biotherapeutics, Ltd. He serves as Founding Partner at Just Biotherapeutics, Inc. Dr. Zhao is a Venture Partner at Lilly Asia Ventures (Lilly Asia Fund) where he is mainly responsible for the operation and management of early investment projects. He is Executive Strategy Director at Global Commercial Operations of Amgen based in Thousand Oaks, California. Dr. Zhao is leading the market entry strategy, business development and commercialization of a portfolio of oncology and inflammatory biologic medicines in 30 countries outside United States and Europe. Previously, he served as Vice President for Emerging Markets Strategy and Business Operations at Amgen. He also served as the Asia Pacific Region Strategic Director at Pfizer New York where he was responsible for the development strategies of new markets especially in the Asia Pacific region and management of cooperation projects on research and development. Dr. Zhao was the Asia Strategy Lead overseeing the Asia strategy across small molecule, biologics, and vaccine. He served as the Interim Head of Pfizer's Bio-Enhancement Development Unit from 2009 to 2010 in charge of the biosimilar and biobetter strategy development and business operation. Dr. Zhao started his pharmaceutical career at Amgen in 1999, then joined Pfizer in 2004, and returned to Amgen. He has experience on strategy management, Asia business development, product development and post-M&A integration. Dr. Zhao had contributed more than thirty peer-reviewed publications and book chapters. He was nominated for American Chemical Society's Young Investigator's Award in 2006. Dr. Zhao holds a Ph.D. in Analytical Chemistry from the Ghent University. He holds a Master's degree in Business Administration from the Massachusetts Institute of Technology and Bachelor's degree in Medicinal Chemistry from Fudan University.